From Living Room to Laboratory: New Dementia Study to Close Participation Gap

Why It Matters

Closing the participation gap ensures new therapies are tested on the population most affected, speeding up development of personalised dementia treatments and improving health outcomes.

Key Takeaways

• Over‑65s make up two‑thirds dementia cases, only one‑third trial participants.
• Cera will bring study to homes, targeting 1,000 dementia patients.
• GlobalMinds merges NHS records, DNA, and questionnaire data.
• Real‑world data aims to enable precision medicine for dementia.
• Study supports NIHR mandate for inclusive clinical research.

Pulse Analysis

Dementia now tops the UK mortality chart, claiming over 76,000 lives annually and projected to affect 1.4 million people by 2040. Yet older adults—who bear the brunt of the disease—are dramatically under‑represented in clinical trials, creating an evidence gap that hampers drug efficacy assessments. The new Cera‑GlobalMinds study directly addresses this mismatch by moving the laboratory into patients' living rooms, ensuring that data reflects everyday realities rather than isolated clinic visits.

The collaboration leverages Cera’s digital‑first home‑care platform, which logs millions of health interactions each month, and GlobalMinds’ expertise in merging electronic health records with genomic and questionnaire data. Participants provide saliva or blood samples, enabling researchers to overlay genetic markers onto longitudinal health trajectories captured during routine home visits. This multi‑modal approach mirrors the precision‑medicine breakthroughs seen in oncology, promising to identify causal pathways, refine diagnostic timelines, and tailor interventions to individual biological profiles.

For the broader health‑tech ecosystem, the study sets a precedent for inclusive, real‑world research at scale. It satisfies the NIHR’s call for older‑adult participation, potentially reshaping funding priorities and regulatory expectations. Pharma companies stand to gain richer, more representative datasets that can de‑risk development pipelines, while clinicians may soon access tools that predict disease progression with unprecedented accuracy. Ultimately, turning living rooms into laboratories could accelerate the delivery of effective, personalized dementia therapies, benefitting patients, caregivers, and the UK’s strained healthcare system.